A new era of immune therapy in multiple myeloma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Lymphocytes from B-acute lymphoblastic leukemia patients present differential regulation of the adenosinergic axis depending on risk stratification.Discover oncology · 2022
   Article
2. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.Annals of hematology · 2022
   Review
3. Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma.Frontiers in immunology · 2021
   Article
4. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.Cancers · 2020
   Review
5. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.Frontiers in immunology · 2020
   Article
6. Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.Antibodies (Basel, Switzerland) · 2017
   Review
7. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
   Article
8. Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.Blood cancer journal · 2017
   Article
9. Should minimal residual disease negativity be the end point of myeloma therapy?Blood advances · 2017
   Article
10. Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.Experimental hematology & oncology · 2017
    Review

Corrections and comments

• Comment on
  Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as